Keywords: GW Pharma, Almirall, Sativex, Germany, Spasticity, MS, Multiple sclerosis

German approval for GW and Almirall’s Sativex for spasticity due to MS

Article | 27 May 2011

Print This

Spain’s leading drugmaker Almirall (ALM) and UK-based originator of the cannabis based product GW Pharmaceuticals (AIM: GWP) say ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in